Digest Network Come funziona
Network
/
Società
Ap
Non verificato

Aptar Pharma

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaSaluteSanità

10 comunicati stampa

Guarda tutti i comunicati
25/09/2025
Industria
Scienza
Attrezzature medico-sanitarie
Medicina - Varie
Sanità
Biotecnologia
Farmaceutica
Salute
Aptar Pharma Continues Global Expansion with Opening of New R&D Center in France
Fonte
Aptar Pharma
Emittente
Business Wire
1.00
0
18/09/2025
Aptar Pharma’s Unidose System Delivers Enbumyst™, First U.S. FDA-Approved Intranasal Diuretic
Fonte
Aptar Pharma
Emittente
Business Wire
1.00
0
05/09/2025
Aptar Pharma and Dianosic Announce Exclusive Partnership to Advance the Active Resorbable Intranasal Scaffold Platform for the Treatment of Chronic Allergic Rhinitis and Chronic Rhinosinusitis
Fonte
Aptar Pharma
Emittente
Business Wire
1.00
0
29/07/2025
Aptar’s First Nasal Pump Made with 52% Bio-based Material* now Available with Haleon’s Otrivin® Brand
Fonte
Aptar Pharma
Emittente
Business Wire
1.00
0
15/07/2025
Scienza
Tecnologia delle costruzioni
Mercato Immobiliare
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Mercato azionario
Industria
Aptar Pharma Bolsters Clinical Trial Capabilities with Strategic Materials Manufacturing Acquisition
Fonte
Aptar Pharma
Emittente
Business Wire
1.00
0
27/02/2025
RDD Europe 2025, Co-Organized by Aptar Pharma and RDD Online, Celebrates 20 Years
Fonte
Aptar Pharma
Emittente
Business Wire
1.00
0
07/11/2024
Aptar Pharma Enters into Exclusive Agreement with Cambridge Healthcare Innovations to Commercialize the Quattrii Dry Powder Inhaler Platform
Fonte
Aptar Pharma
Emittente
Business Wire
1.00
0
09/10/2024
Aptar Pharma Acquires Device Technology Assets of SipNose to Further Expand Intranasal Drug Delivery Portfolio
Fonte
Aptar Pharma
Emittente
Business Wire
1.00
0
24/09/2024
Aptar Pharma Celebrates North America Capacity Expansion
Fonte
Aptar Pharma
Emittente
Business Wire
1.00
0
09/09/2024
Multimedialità
Mercato del lavoro
Industria
Attrezzature medico-sanitarie
Biotecnologia
Sanità
Salute
Farmaceutica
Aptar Pharma Enters into Exclusive Agreement with Pulmotree to Develop and Promote Kolibri™ Non-Propellant Liquid Inhaler Platform
Fonte
Aptar Pharma
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0